Peijia Medical (HKG:9996) has completed the first two implants with the TrilogyTM Transcatheter Heart Valve System to treat severe aortic regurgitation in Taiwan, China, a Wednesday filing with the Hong Kong bourse said.
The system is indicated for use in patients with symptomatic severe aortic regurgitation or symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
Shares of the company were up over 8% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.